AbCellera Biologics Inc vs iShares MSCI Singapore ETF — how do they compare? AbCellera Biologics Inc trades at $10.23 (market cap $2.99B), while iShares MSCI Singapore ETF trades at $33.66. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, iShares MSCI Singapore ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | EWS | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $9.76 | $33.92 |
52-Week Low | $2.78 | $26.71 |
Enterprise Value | $2.58B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
EWS (iShares MSCI Singapore ETF) trades at $33.66, up 1.48% today and hitting a new 52-week high. Technical indicators show a bullish moving average consensus but overbought RSI signals. The ETF benefits from Singapore's economic resilience and AI-driven growth momentum, with institutional buying from firms like Amundi. Dividend yield remains attractive at 3.97% with consistent payout history.
Outlook remains positive given Singapore's market reforms and AI infrastructure growth, though concentrated financial sector exposure (54%) poses sector-specific risks. Near-term resistance at $34 may challenge further upside without fundamental catalysts. The ETF offers strategic Asian diversification but requires monitoring of regional economic developments.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →